Medical Technology Breaking News: Aethlon Medical
(OTCQB: AEMD) Expands Clinical Research Studies to Include Chikungunya Virus
SAN DIEGO - June 4, 2015 (Investorideas.com
newswire) Aethlon Medical, Inc. (OTCQB:AEMD), the pioneer in creating affinity biofiltration devices to treat
life-threatening diseases, disclosed today that it has entered into an
agreement with the National Institute of Virology (NIV) to begin testing of the
Aethlon Hemopurifier® as a candidate to treat Chikungunya, a debilitating
mosquito-borne virus that is not addressed with proven antiviral drug or
vaccine therapies. In late 2013, Chikungunya was identified for the first time in
the Americas on islands in the Caribbean. Since then, transmission of the virus
has been identified in 44 countries or territories throughout the Americas with
more than 1.2 million suspected cases reported to the Pan American Health
Organization.
The NIV is one of the major institutes of the
Indian Council of Medical Research (ICMR) and is a World Health Organization
(WHO) collaborating center for arbovirus and hemorrhagic virus research. In
previous NIV studies, the Aethlon Hemopurifier® was validated to capture Dengue
virus from human blood serum.
The Aethlon Hemopurifier is an affinity
biofiltration device that targets the rapid elimination of infectious viruses
and cancer promoting exosomes from the circulatory system of treated
individuals. In the treatment of infectious viral pathogens, the Hemopurifier
provides a candidate solution for antiviral drug resistance and serves as a
first-line countermeasure against viruses that are not addressed with proven
drug therapies. To date, Hemopurifier therapy has been successfully
administered to individuals infected with Ebola virus (Ebola), Hepatitis C
virus (HCV) and the Human Immunodeficiency virus (HIV).
A U.S. Food and Drug Administration (FDA) approved
clinical study of Hemopurifier therapy is currently being conducted in
HCV-infected end-stage renal disease patients. Additionally, Hemopurifier
clinical protocols to treat Ebola virus have recently been approved by both the
FDA and the Medical Devices Bureau of Health Canada.
About Aethlon Medical, Inc.
Aethlon
Medical creates affinity biofiltration devices to treat life-threatening
diseases. Our lead therapeutic candidate is the Aethlon Hemopurifier®, a
first-in-class device that targets the rapid elimination of infectious viruses
and cancer promoting exosomes from the circulatory system of treated individuals.
Our majority owned subsidiary Exosome Sciences, Inc., is advancing
exosome-based liquid biopsies to diagnose and monitor Cancer and Chronic
Traumatic Encephalopathy (CTE), a neurodegenerative disorder often found in
individuals with a history of repetitive brain trauma.
About The Aethlon Hemopurifier®
Of
the hundreds of viruses known to be infectious to man, antiviral drug therapies
are approved for fewer than ten. The Aethlon Hemopurifier® provides a
broad-spectrum therapeutic strategy to address drug resistant viral pathogens.
To date, Hemopurifier therapy has been administered to individuals infected
with Ebola virus (Ebola), Hepatitis C virus (HCV) and the Human
Immunodeficiency virus (HIV). Time Magazine recently named the Hemopurifier to their
list of 'Top 25 Inventions" and "The 11 Most Remarkable Advances in
Healthcare." Beyond human treatment experiences, pre-clinical Hemopurifier
studies have validated the capture of some of world's deadliest pathogens.
These include: Dengue hemorrhagic fever, Lassa hemorrhagic fever, H5N1 avian
influenza, H1N1 swine flu virus, the reconstructed 1918 influenza virus, West
Nile virus and Vaccinia and Monkeypox, which serve as models for human smallpox
infection. U.S. clinical progression of Hemopurifier therapy is being advanced
under FDA approved clinical studies.
Aethlon
is also investigating the use of Hemopurifier therapy to capture tumor-derived
exosomes, a significant unaddressed therapeutic target in cancer care.
Tumor-derived exosomes promote cancer progression through multiple mechanisms,
which include seeding the spread of metastasis and direct suppression of the
immune response. In regards to our therapeutic mechanism of action, the
Hemopurifier incorporates a patented affinity technique that allows for
selective binding to a unique structure that resides on the surface of
tumor-derived exosomes and glycoproteins that coat infectious viruses.
Additional information can be found online at www.AethlonMedical.com or you can connect with us on on http://www.aethlonmedical.com/ and connect with
the Company on Twitter, LinkedIn, Facebook and Google+.
Certain
statements herein may be forward-looking and involve risks and uncertainties.
Such forward-looking statements involve assumptions, known and unknown risks,
uncertainties and other factors which may cause the actual results, performance
or achievements of Aethlon Medical, Inc. to be materially different from any
future results, performance, or achievements expressed or implied by the
forward-looking statements. Such potential risks and uncertainties include,
without limitation, that the ESI will not be able to commercialize its future
products, that the FDA will not approve the initiation of the Company's
clinical programs or provide market clearance of the company's products, future
human studies whether revenue or non-revenue generating of the Aethlon ADAPT™
system or the Aethlon Hemopurifier® as an adjunct therapy to improve patient
responsiveness to established cancer or hepatitis C therapies or as a
standalone cancer or hepatitis C therapy or as a broad spectrum defense against
viral pathogens, including Ebola, the Company's ability to raise capital when
needed, the Company's ability to complete the development of its planned
products, the Company's ability to manufacture its products either internally
or through outside companies and provide its services, the impact of government
regulations, patent protection on the Company's proprietary technology, the
ability of the Company to meet the milestones contemplated in the DARPA
contract, product liability exposure, uncertainty of market acceptance,
competition, technological change, and other risk factors. In such instances,
actual results could differ materially as a result of a variety of factors,
including the risks associated with the effect of changing economic conditions
and other risk factors detailed in the Company's Securities and Exchange
Commission filings. The Company undertakes no obligation to publicly update or
revise any forward-looking statements, whether as a result of new information,
future events, or otherwise.
Contacts:
David
Zazoff
MDM Worldwide Solutions
646-403-3554
MDM Worldwide Solutions
646-403-3554
Sign up
for the free investor news and stock alerts:
Disclaimer/Disclosure: The Investorideas.com newswire is a third party
publisher of news and research as well as creates original content as a news
source. Original content created by investorideas is protected by copyright
laws other than syndication rights. Investorideas is a news source on Google
news and Linkedintoday plus hundreds of syndication partners. Our site does not
make recommendations for purchases or sale of stocks or products. Nothing on
our sites should be construed as an offer or solicitation to buy or sell products
or securities. All investment involves risk and possible loss of investment.
This site is currently compensated by featured companies, news submissions,
content marketing and online advertising. Contact each company directly for
press release questions. Disclosure is posted on each release if required but
otherwise the news was not compensated for and is published for the sole
interest of our readers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp
Disclosure:
AEMD subscribes to the Investorideas newswire content publishing annual program
(9700 per Year, paid quarterly) for news publishing.
BC
Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors
should review all OTC and Pink sheet listed companies for adherence in new
disclosure filings and filing appropriate documents with Sedar. Read for more
info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors
must adhere to regulations of each country.
